# A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer

> **NCT06340165** · — · UNKNOWN · sponsor: **The First Hospital of Jilin University** · enrollment: 153 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT06340165
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02-04
- **Primary completion:** 2025-06
- **Final completion:** 2025-06
- **Target enrollment:** 153 (ESTIMATED)
- **Last updated:** 2024-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06340165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06340165, "A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06340165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*